DE602004027637D1 - Verwendung von cupredoxin-proteine für krebstherapie - Google Patents

Verwendung von cupredoxin-proteine für krebstherapie

Info

Publication number
DE602004027637D1
DE602004027637D1 DE602004027637T DE602004027637T DE602004027637D1 DE 602004027637 D1 DE602004027637 D1 DE 602004027637D1 DE 602004027637 T DE602004027637 T DE 602004027637T DE 602004027637 T DE602004027637 T DE 602004027637T DE 602004027637 D1 DE602004027637 D1 DE 602004027637D1
Authority
DE
Germany
Prior art keywords
cancer therapy
cupredoxin
proteins
cupredoxin proteins
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004027637T
Other languages
English (en)
Inventor
Amanda M Chakrabarty
Gupta Tapas K Das
Vasu Punj
Olga Zaborina
Yoshinori Hiraoka
Tohru Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
Original Assignee
University of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois filed Critical University of Illinois
Publication of DE602004027637D1 publication Critical patent/DE602004027637D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
DE602004027637T 2003-08-15 2004-08-10 Verwendung von cupredoxin-proteine für krebstherapie Active DE602004027637D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41455003P 2003-08-15 2003-08-15
US10/720,603 US7491394B2 (en) 2001-02-15 2003-11-24 Cytotoxic factors for modulating cell death
PCT/US2004/025982 WO2005018662A1 (en) 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy

Publications (1)

Publication Number Publication Date
DE602004027637D1 true DE602004027637D1 (de) 2010-07-22

Family

ID=34221130

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027637T Active DE602004027637D1 (de) 2003-08-15 2004-08-10 Verwendung von cupredoxin-proteine für krebstherapie

Country Status (19)

Country Link
US (4) US7491394B2 (de)
EP (2) EP2263682A1 (de)
JP (1) JP2007502818A (de)
KR (1) KR20060098358A (de)
AP (1) AP2006003537A0 (de)
AT (1) ATE470672T1 (de)
AU (1) AU2004266632A1 (de)
BR (1) BRPI0413574A (de)
CA (1) CA2535581A1 (de)
DE (1) DE602004027637D1 (de)
EA (1) EA009897B1 (de)
EC (1) ECSP066422A (de)
GE (1) GEP20105022B (de)
IL (1) IL173576A0 (de)
NO (1) NO20061168L (de)
NZ (1) NZ545355A (de)
OA (1) OA13308A (de)
TN (1) TNSN06059A1 (de)
WO (1) WO2005018662A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7618939B2 (en) 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
CN101437842A (zh) 2004-10-07 2009-05-20 阿南达·查克拉博蒂 铜氧还蛋白衍生的转运制剂及其应用方法
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
EP1888106A4 (de) * 2005-05-20 2009-01-14 Univ Illinois Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen
EP1882039A4 (de) * 2005-05-20 2008-08-20 Univ Illinois Zusammensetzungen und verfahren zur behandlung von malaria mit cupredoxin und cytochrom
BRPI0612431A2 (pt) * 2005-05-20 2009-02-10 Univ Illinois composiÇÕes e mÉtodos para o tratamento da infecÇço hiv com cupredoxina e citocromo c
AU2006269879A1 (en) * 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
KR20080034905A (ko) * 2005-07-19 2008-04-22 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 혈관신생을 제어하는 조성물과 방법
US10266868B2 (en) 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
RU2009113562A (ru) * 2006-09-11 2010-10-20 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Модификации пептидов, происходящих из купредоксина, и способы их применения
KR20090059152A (ko) * 2006-09-14 2009-06-10 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 암을 예방하는 조성물과 방법
JP2010511408A (ja) 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
WO2008086523A2 (en) * 2007-01-11 2008-07-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
WO2008098216A2 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
JP5658157B2 (ja) * 2008-09-18 2015-01-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ピロリジン−２−カルボキサミド
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
US20180002664A1 (en) 2014-12-19 2018-01-04 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
US11136613B2 (en) 2015-04-30 2021-10-05 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
CN111705026B (zh) * 2020-06-02 2021-11-26 华中农业大学 一种牛支原体Mbov_0280基因突变株及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585644A (en) 1984-06-04 1986-04-29 Phillips Petroleum Company Changing oil tubes in a carbon black reactor
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
ATE295895T1 (de) 1992-03-11 2005-06-15 Powderject Vaccines Inc Genetischer impfstoff gegen den immunschwäche virus
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
WO1994015635A1 (en) 1993-01-11 1994-07-21 Dana-Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
KR100955974B1 (ko) 2001-02-15 2010-05-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 세포 사멸을 조절하는 세포독성인자
UA88272C2 (ru) 2003-08-15 2009-10-12 Борд Оф Трастиз Оф Зе Юниверсити Оф Иллинойс Применение полипептидов семейства купредоксина в лечении рака
CN101437842A (zh) 2004-10-07 2009-05-20 阿南达·查克拉博蒂 铜氧还蛋白衍生的转运制剂及其应用方法
BRPI0612431A2 (pt) 2005-05-20 2009-02-10 Univ Illinois composiÇÕes e mÉtodos para o tratamento da infecÇço hiv com cupredoxina e citocromo c
EP1882039A4 (de) 2005-05-20 2008-08-20 Univ Illinois Zusammensetzungen und verfahren zur behandlung von malaria mit cupredoxin und cytochrom
AU2006269879A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof

Also Published As

Publication number Publication date
ECSP066422A (es) 2006-11-24
TNSN06059A1 (en) 2007-10-03
NO20061168L (no) 2006-05-15
AP2006003537A0 (en) 2006-04-30
US7491394B2 (en) 2009-02-17
WO2005018662A1 (en) 2005-03-03
ATE470672T1 (de) 2010-06-15
EA009897B1 (ru) 2008-04-28
KR20060098358A (ko) 2006-09-18
US10421801B2 (en) 2019-09-24
US20060040269A1 (en) 2006-02-23
OA13308A (en) 2007-04-13
AU2004266632A1 (en) 2005-03-03
BRPI0413574A (pt) 2006-10-17
JP2007502818A (ja) 2007-02-15
IL173576A0 (en) 2006-07-05
EA200600424A1 (ru) 2006-08-25
CA2535581A1 (en) 2005-03-03
EP1653990A1 (de) 2006-05-10
GEP20105022B (en) 2010-06-25
EP1653990B1 (de) 2010-06-09
US20140179617A1 (en) 2014-06-26
US20060292136A1 (en) 2006-12-28
US20080182782A1 (en) 2008-07-31
EP2263682A1 (de) 2010-12-22
NZ545355A (en) 2009-10-30
US7888468B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
DE60315135D1 (de) Therapiesonde
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
IL181779A (en) A group of protein-based medical molecules
DK1755671T3 (da) Terapi af platinresistent cancer
DE60321130D1 (de) Variation von parametern zur neurostimulation
DE502005006470D1 (de) Verwendung von sulfonylharnstoffen
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
ATE417842T1 (de) Verwendung von trisubstituierten benzopyranonen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
NO20053956D0 (no) Brystkreftresistentsprotein (BCRP)-inhibitor
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602005001066D1 (de) Komplexe Emulsionen von Perfluoropolyethern
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
ATE457168T1 (de) Transdermales therapeutisches system von gestoden
DE50311406D1 (de) Verwendung von Formkörpern
DE602004026773D1 (de) Verfahrensherstellung von ethern
ATE455770T1 (de) N-alkynyl-2-heteroaryloxyalkylamide zur verwendung als fungizide
DE50308460D1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE502004002460D1 (de) Verwendung von copolymerisaten als hilfsmittel für die lederherstellung
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung
ATE521351T1 (de) Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren
ATE348606T1 (de) Neue verwendung von pipatalin
DE502004000494D1 (de) Schrittschaltwerk